May 21, 2019

Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF)(the "Company" or "Kalytera") has engaged Echelon Wealth Partners to determine the value, on a risk-adjusted...
April 17, 2019

Kalytera Therapeutics Announces Filing of Short Form Prospectus

Kalytera Therapeutics, Inc. (the “Company”, or “Kalytera”) (TSXV:KALY) (OTCQB:KALTF) announced today that it has filed a final short form prospectus...
April 3, 2019

Kalytera Therapeutics Announces Short Form Prospectus Offering of Units

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) announced that it has filed a preliminary short form prospectus with the securities regulatory authorities...
March 24, 2019

Cannabis Pharmaceuticals: Global Legitimacy Through Medical Cannabis Research Programs

Medical cannabis research programs are giving global legitimacy to cannabis therapeutics.
March 22, 2019

Kalytera Reports Data for First Cohort in Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

Kalytera Therapeutics, Inc. (TSXV:KALY, OTC:KALTF) (the "Company" or "Kalytera") today announced positive data from its ongoing Phase 2 clinical study evaluating...
March 6, 2019

Kalytera Announces Initiation of Study KAL-07 – Food Effect Study

Kalytera Therapeutics, Inc. (TSXV:KALY, OTC:KALTF) (the "Company" or "Kalytera") today announced that it has initiated a food effect study (“Study...
March 5, 2019

Kalytera Announces Private Placement of Convertible Debenture Units

Kalytera Therapeutics, Inc. (TSXV:KALY and OTC:KALTF) (the "Company" or "Kalytera") announced today that it is proceeding with a private placement...